Format

Send to

Choose Destination
Leukemia. 2014 Apr;28(4):961-4. doi: 10.1038/leu.2014.21. Epub 2014 Jan 14.

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein.

Author information

1
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
2
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St John's University, Queens, NY, USA.
3
NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, Rockville, MD, USA.
PMID:
24418991
PMCID:
PMC3981924
DOI:
10.1038/leu.2014.21
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center